Seeking Alpha

Navidea Bio soars on Fast Track designation for Lymphoseek

  • Navidea Biopharmaceuticals (NAVB) jumps 30% in premarket trading.
  • The company says the FDA has granted a Fast Track designation to Lymphoseek for "sentinel lymph node detection in patients with head and neck cancer."
  • The radiopharmaceutical is currently approved for use in helping to diagnose the spread of breast cancer and melanoma.
  • NAVB says it expects to file an sNDA "before year-end." (PR)
Comments (3)
  • Great news, like the company management!
    10 Dec 2013, 09:10 AM Reply Like
  • Ye, patience is rewarding! Sticking with this company at lease till $5.00 a share.
    10 Dec 2013, 09:36 AM Reply Like
  • Been holding this stock for over 15 years. Still think it is a good long term investment. I don't plan on selling soon.
    13 Dec 2013, 03:11 PM Reply Like
DJIA (DIA) S&P 500 (SPY)